Length increase of the side chain of idoxifene does not improve its antagonistic potency in breast-cancer cell lines.

Abstract

Linkage of specific residues onto steroidal estrogens through a long aliphatic side chain leads to "pure antiestrogens" devoid of residual estrogenic activity. Therefore, we assessed whether an increase in the length of the side chain of the triphenylethylenic antiestrogen idoxifene might increase its antagonistic potency. Culture of MCF-7 and tamoxifen-resistant variant RTX6 cells in the presence of CB 7675, a (CH2)8 derivative of idoxifene [(CH2)2], ruled out this possibility. This compound partly blocked MCF-7 cell growth only at 10(-6) M to almost the same extent as tamoxifen and failed to inhibit the growth of RTX6 cells, whereas the pure antiestrogen RU 58 668 was effective on both cell lines at much lower concentration. This absence of improvement was reflected in the observation of an efficiency for down-regulating progesterone receptor no better than that of tamoxifen. Pure antiestrogens are known to down-regulate the estrogen receptor, whereas triphenylethylenic antiestrogens up-regulate the receptor; CB 7675 behaves as the latter in agreement with its lack of strong antagonistic activity.

• Authors: L Jin, N Legros, G Leclercq, I R Hardcastle, M Jarman
• Journal: Cancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 41 Issue 4 Pg. 339-42 ( 1998) ISSN: 0344-5704 [Print] Germany
• PMID: 9488604 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Estrogen Antagonists
• Receptors, Estrogen
• Receptors, Progesterone
• Tamoxifen
• idoxifene

Topics

• Breast Neoplasms (pathology)
• Cell Division (drug effects)
• Estrogen Antagonists (pharmacology)
• Female
• Humans
• Receptors, Estrogen (drug effects)
• Receptors, Progesterone (drug effects)
• Structure-Activity Relationship
• Tamoxifen (analogs & derivatives, pharmacology)
• Tumor Cells, Cultured (drug effects)